We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
PLx Pharma Inc | NASDAQ:PLXP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.087 | 0.0861 | 0.089 | 0 | 01:00:00 |
2021 Fourth Quarter Conference Call
Date | Friday, March 11, 2022 |
Time | 8:30 a.m. ET |
Toll free (U.S.) | (866) 394-2901 |
International | (616) 548-5567 |
Conference ID | 2664996 |
Webcast (live and replay) | https://ir.plxpharma.com/investor-relations |
A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International). The conference ID for the replay is 2664996. The archived webcast will be available via PLx Pharma’s investor relations website for 30 days after the call.
About VAZALORE VAZALORE is an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. VAZALORE delivers aspirin differently from plain and enteric coated aspirin products. The special complex inside the capsule is designed for targeted release of aspirin, limiting its direct contact with the stomach. VAZALORE delivers fast, reliable absorption for pain relief plus the lifesaving benefits of aspirin. To learn more about VAZALORE, please visit www.vazalore.com.
About PLx Pharma Inc. PLx Pharma Inc. is a commercial-stage drug delivery platform technology company focused on improving how and where active pharmaceutical ingredients (APIs) are absorbed in the gastrointestinal (GI) tract via its clinically validated and patent protected PLxGuard™ technology. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach injury associated with certain drugs. To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.
Contacts:Janet M. BarthVice President, Investor Relations & Corporate Communications, PLx Pharma Inc.(973) 409-6542IR@PLxPharma.com
Lisa M. WilsonFounder & President, In-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com
1 Year PLx Pharma Chart |
1 Month PLx Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions